Abstract
Get full access to this article
View all access options for this article.
References
1.
Magenta Therapeutics. Magenta Therapeutics to explore strategic alternatives. February 2, 2023. https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-explore-strategic-alternatives (last accessed
February 12 , 2023
).
2.
Magenta Therapeutics. Magenta Therapeutics voluntarily pauses the MGTA-117 Phase 1/2 dose-escalation clinical trial to investigate drug safety. January 25, 2023. https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-voluntarily-pauses-mgta-117-phase-12-dose (last accessed
February 12 , 2023
).
3.
4D Molecular Therapeutics. Form 8-K, filed February 3, 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/0001650648/000119312523023004/d435190d8k.htm (last accessed
February 12 , 2023
).
4.
Vertex Pharmaceuticals. Vertex Pharmaceuticals Q4 2022 conference call. February 7, 2023. https://event.webcasts.com/starthere.jsp?ei=1594238&tp_key=27b649c224 (last accessed
February 13 , 2023
).
5.
Taysha Gene Therapies. GAN program update and 2023 corporate outlook conference call. January 31, 2023. https://viavid.webcasts.com/starthere.jsp?ei=1595611&tp_key=2db30e6665 (last accessed
February 12 , 2023
).
6.Roche. Roche finance report 2022. February 2, 2023 . https://assets.cwp.roche.com/f/126832/x/8971737b76/fb22e.pdf (last accessed
February 12 , 2023
).
7.Rocket Pharmaceuticals. Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy (RMAT) designation for RP-A501 gene therapy for Danon disease . https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-receives-fda-regenerative-medicine-1 (last accessed
February 12 , 2023
).